Leveraging AI: The Biotech Cracking the Code on Rare Diseases
TICKER
ganx
market cap:
$65m
Risk Rating:
SECTOR: BIOTECH
Leveraging AI: The Biotech Cracking the Code on Rare Diseases
In this candid conversation, Lou Basenese sits down with Gene Mack, CEO of Gain Therapeutics, to reveal how the company is leveraging AI to unlock billion-dollar opportunities in rare and neurodegenerative diseases. Mack highlights a striking disconnect: a $70 million company with a Phase 2 Parkinson’s drug that could be disease-modifying. He outlines Gain’s vast revenue potential and why future therapies will be measured against its first-in-class platform.
Want to be Featured on The Upside?
Apply for the next season of interviews.
Looking to get in front of investors who actually pay attention? Partner with TheBigSkinny.com and The Upside to access our fast-growing audience of engaged, idea-hungry investors who come to us for fresh takes and smart opportunities. Whether you’re launching something new or looking to build long-term visibility, we help you cut through the noise and get noticed by the right people.
